Leap Therapeutics (LPTX) PT Raised to $5 at Piper Sandler Following Positive Data at ESMO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Leap Therapeutics (LPTX) Prices $90M Share and Warrant Offering at $2.85/sh
September 22, 2021 8:31 AM EDTLeap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the pricing of an underwritten public offering of its common stock at a public offering price of $2.85 per share and of pre-funded warrants to purchase shares of its common stock at a public offering price of $2.849 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. The gross proceeds to Leap from this offering are expected to be approximately $90 million, before deducting... More
Leap Therapeutics (LPTX) Climbs 58%
September 16, 2021 6:08 AM EDTLeap Therapeutics (NASDAQ: LPTX) Climbs 58%
Earlier Leap Therapeutics (LPTX) Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab... MoreLeap Therapeutics (LPTX) Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab
September 16, 2021 5:55 AM EDTLeap Therapeutics, Inc. (Nasdaq: LPTX) today announced the presentation of updated positive data from the first-line cohort of the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene Ltd.'s anti-PD-1 antibody, and chemotherapy, in patients with gastric or gastroesophageal junction cancer (G/GEJ), at the European Society for Medical Oncology (ESMO) Congress.... More
